Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL2781361 | 1.00 | TSHR (0.58) | TSHRTHRBLMNANAAASLC22A1 | |
| Hexane SCHEMBL275495 | 1.00 | TSHR (0.58) | TSHRTHRBLMNANAAASLC22A1 | |
| Hexane SCHEMBL275309 | 1.00 | — | — | |
| Dodecane SCHEMBL28138522 | 0.96 | TSHR (0.67) | TSHRTHRBLMNANAAASLC22A1 | |
| Heptane SCHEMBL28355078 | 0.96 | TSHR (0.67) | TSHRTHRBLMNANAAASLC22A1 | |
| Hexadecane SCHEMBL28842818 | 0.96 | TSHR (0.67) | TSHRTHRBLMNANAAASLC22A1 | |
| Pentane SCHEMBL10582130 | 0.91 | — | — | |
| Hexane SCHEMBL21496135 | 0.84 | — | — | |
| Hexane SCHEMBL28393830 | 0.84 | TSHR (0.50) | TSHRTHRBLMNANAAASLC22A1 | |
| Isothiocyanate SCHEMBL7133121 | 0.81 | TSHR (0.57) | TSHRTHRBLMNANAAASLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116521-B1 | PROCESS FOR PRODUCING FULLERENE DERIVATIVE | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-8134019-B2 | Process for producing fullerene derivative | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100048934-A1 | PROCESS FOR PRODUCING FULLERENE DERIVATIVE | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2116521-A1 | PROCESS FOR PRODUCING FULLERENE DERIVATIVE | Japan Science and Technology Agency (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048934-A1 | PROCESS FOR PRODUCING FULLERENE DERIVATIVE | INF2, EIF4B, C9 | TSHR 4259/4885THRB 4475/4885LMNA 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.